Myriad Genetics (MYGN) Accounts Payables (2010 - 2026)

Myriad Genetics (MYGN) has 17 years of Accounts Payables data on file, last reported at $32.6 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $32.6 million, up 16.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $32.6 million (up 16.01% YoY), and the FY2025 annual result was $30.0 million, down 7.12% from the prior year.
• Accounts Payables improved to $32.6 million in Q1 2026 per MYGN's latest filing, from $30.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $39.8 million in Q2 2023 and troughed at $21.7 million in Q2 2022.
• A 5-year average of $30.9 million and a median of $30.9 million in 2025 frame the typical range for Accounts Payables.
• On a YoY basis, Accounts Payables climbed as much as 88.54% in 2022 and fell as far as 23.86% in 2022.
• A 5-year view of Accounts Payables shows it stood at $28.8 million in 2022, then retreated by 10.42% to $25.8 million in 2023, then grew by 25.19% to $32.3 million in 2024, then dropped by 7.12% to $30.0 million in 2025, then rose by 8.67% to $32.6 million in 2026.
• Business Quant data shows MYGN's Accounts Payables at $32.6 million in Q1 2026, $30.0 million in Q4 2025, and $31.8 million in Q3 2025.